DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactEarnings

Natco Pharma Limited — Board Meeting Intimation

NSE 2 hrs ago·22 Sept 2026, 12:31 pm

Natco Pharma

Natco Pharma has announced that its board will meet on September 25, 2026, to discuss and possibly approve a fund-raising plan. This is a standard corporate procedure where the company seeks to raise capital from the market.

For investors, this news is generally seen as a positive development. It indicates that the company is exploring options to strengthen its balance sheet, which could be used for debt repayment, funding new projects, or general business expansion. It signals management's confidence in future growth.\n Investors should watch for the specific details of the fund-raising, such as the amount and the method (like a rights issue or private placement). The announcement will provide clarity on how the company plans to utilize the new capital.